Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury

Martin-Liberal, 2017, The expanding role of immunotherapy, Cancer Treat Rev, 54, 74, 10.1016/j.ctrv.2017.01.008 Kumar, 2017, Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy, Front Pharmacol, 8, 49, 10.3389/fphar.2017.00049 Friedman, 2016, Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review, JAMA Oncol, 2, 1346, 10.1001/jamaoncol.2016.1051 Haanen, 2017, Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 28, iv119, 10.1093/annonc/mdx225 Mian, 2016, Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab, J Clin Oncol, 34, 3047, 10.1200/JCO.2016.34.15_suppl.3047 Wang, 2017, Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data, Int J Cancer, 141, 1018, 10.1002/ijc.30678 Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, 23, 10.1056/NEJMoa1504030 Kim, 2013, Ipilimumab associated hepatitis: imaging and clinicopathologic findings, Invest New Drugs, 31, 1071, 10.1007/s10637-013-9939-6 Johncilla, 2015, Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases, Am J Surg Pathol, 39, 1075, 10.1097/PAS.0000000000000453 Abdel-Wahab, 2016, Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports, PLoS One, 11, 10.1371/journal.pone.0160221 Tanaka, 2017, Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab, Jpn J Clin Oncol, 47, 175, 10.1093/jjco/hyw167 Della Vittoria Scarpati, 2014, Ipilimumab in the treatment of metastatic melanoma: management of adverse events, Onco Targets Ther, 7, 203, 10.2147/OTT.S57335 Spänkuch, 2017, Severe hepatitis under combined immunotherapy: resolution under corticosteroids plus anti-thymocyte immunoglobulins, Eur J Cancer, 81, 203, 10.1016/j.ejca.2017.05.018 Nakanuma, 2001, Pathology and pathogenesis of intrahepatic bile duct loss, J Hepatobiliary Pancreat Surg, 8, 303, 10.1007/s005340170002 Reau, 2008, Vanishing bile duct syndrome, Clin Liver Dis, 12, 203, 10.1016/j.cld.2007.11.007 Kamihira, 2005, Biliary epithelial cells regulate autoreactive T cells: implications for biliary-specific diseases, Hepatology, 41, 151, 10.1002/hep.20494 Ayres, 1993, Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: effect of pro-inflammatory cytokines, Gut, 34, 1245, 10.1136/gut.34.9.1245 Cruickshank, 1998, Expression and cytokine regulation of immune recognition elements by normal human biliary epithelial and established liver cell lines in vitro, J Hepatol, 29, 550, 10.1016/S0168-8278(98)80149-9 Kawakami, 2017, Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer, Invest New Drugs, 35, 529, 10.1007/s10637-017-0453-0